Xencor (XNCR) Change in Accured Expenses (2013 - 2026)
Xencor (XNCR) reported Change in Accured Expenses of -$707000.0 for Q1 2026, up 77.58% year-over-year from -$398121.4 in Q1 2025, and down 110.18% quarter-over-quarter from $6.9 million in Q4 2025.
Xencor (XNCR) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Change in Accured Expenses data on file, last reported at -$707000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$707000.0, up 77.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.2 million (up 531.53% YoY), and the FY2025 annual result was $13.8 million, up 417.37% from the prior year.
- Change in Accured Expenses fell to -$707000.0 in Q1 2026 per XNCR's latest filing, from $6.9 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $6.9 million in Q4 2025 and troughed at -$10.1 million in Q1 2024.
- A 5-year average of $756647.1 and a median of $2.9 million in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 581.72% in 2024, then jumped 212.15% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at -$561000.0 in 2022, then slumped by 61.85% to -$908000.0 in 2023, then plunged by 581.72% to -$6.2 million in 2024, then jumped by 212.15% to $6.9 million in 2025, then slumped by 110.18% to -$707000.0 in 2026.
- Business Quant data shows XNCR's Change in Accured Expenses at -$707000.0 in Q1 2026, $6.9 million in Q4 2025, and $4.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -707,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -707,000.00 |
| Mar 31, 2026 | -707,000.00 |
| Dec 31, 2025 | 6.94 Mn |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Mar 31, 2024 | -10.07 Mn |
| Mar 31, 2024 | -10.07 Mn |
| Dec 31, 2023 | -908,000.00 |
| Dec 31, 2023 | -908,000.00 |